NRx Pharmaceuticals Announces Findings In Phase 2b/3 Clinical Trial Of NRX-101 Vs. Lurasidone For Treatment Of Suicidal Bipolar Depression, Says Demonstrated A 'Promising, Though Not yet Statistically Significant 33% Reduction in Suicidality Together With a 70% Reduction' In Symptoms Of Akathisia
nRx Pharmaceuticals 公佈了 NRX-101 Vs. 2b/3 期臨床試驗的結果據說，用於治療自殺性雙相抑鬱症的盧拉西酮顯示 “自殺率有望降低33％，靜坐症狀減少了70％，但尚未具有統計學意義”